NASDAQ:SABS
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc.'s revenue fell 100.0% in fiscal 2025 to $0. Free cash flow was −$45.7M, and the diluted share count rose 562.3%.Summary generated from SAB Biotherapeutics, Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity15.0%
Debt / equityn/a
Free cash flow−$45.7M
FCF marginn/a
Share count change+562.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 61 | 24 | 2 | 1 | 0 |
| Operating income | −13 | −29 | −38 | −43 | −49 |
| Net income | −17 | −19 | −42 | −34 | 13 |
| Free cash flow | −9 | −26 | −25 | −35 | −46 |
Recent filings
- 4Insider transaction report
Sep 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KRegulation FD disclosure
Jul 7, 2026 - 4Insider transaction report
Jun 26, 2026 - 8-KResults of a shareholder vote
Jun 18, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - 8-KEntry into a material agreement
May 4, 2026 - DEF 14AProxy statement
Apr 30, 2026